MenB Vaccines and VFC

New MenB Vaccines

The VFC Program now offers the two recently licensed meningococcal B vaccines, Bexsero®, manufactured by GlaxoSmithKline, and Trumenba®, manufactured by Pfizer Inc.

Meningococcal Group B Vaccines (MenB)

Both Bexsero® and Trumenba® are recombinant vaccines licensed in the United States for prevention of meningococcal serotype B disease in indicated persons 10 – 25 years of age. Meningococcal disease is a life-threatening illness caused by bacteria that can cause sepsis and meningitis. Thirteen different meningococcal serogroups have been defined, five of which cause the great majority of disease (A, B, C, Y, and W135). According to the CDC, approximately 500 total cases of meningococcal disease were reported in the U.S. in 2012, of which 160 (32%) were caused by serogroup B. The majority of the other cases of meningococcal disease were caused by the serogroups A, C, Y, and W135. Invasive disease with these 4 serogroups are preventable by meningococcal conjugate quadrivalent vaccines (MCV4; Menactra®, Sanofi Pasteur; Menveo®, GlaxoSmithKline), which have been supplied by VFC for many years.

The Philadelphia VFC Program will supply either of the two vaccines to VFC providers – at their choice – for VFC-eligible, medically-indicated patients 10 – 18 years of age, as detailed below.

Recommendations for Use of MenB Vaccines for VFC-Eligible Children

MenB should be administered to children 10 – 15 years of age at increased risk of meningococcal disease, due to one of the following:

  1. Children 10 – 15 years of age with persistent complement component deficiencies;
  2. Children 10 – 15 years of age with anatomic or functional asplenia;
  3. Children 10 – 15 years of age at risk because of a serogroup B meningococcal outbreak.

MenB may be administered to children 16 – 18 years of age who are determined to be at increased risk of meningococcal type B disease.

Administration of MenB Vaccines

Bexsero® vaccine is licensed as a two-dose schedule, given at least 28 days apart, i.e., at 0 and 1 month. Trumenba® vaccine is licensed as a three-dose schedule, given at 0, 1 – 2 months, and 6 months. Both Bexsero® and Trumenba® are supplied in 0.5 mL prefilled syringes, to be administered via intramuscular injection into the deltoid muscle of the upper arm. If vaccine is administered at intervals longer than recommended, there is no need to restart the series. Each MenB vaccine can be administered at the same visit as all other indicated vaccines.

Read the PDF here.

Returning VFC/VFAAR Influenza Vaccine

Return All Unopened VFC/VFAAR Influenza Vaccine

All VFC and VFAAR 2014-15 seasonal flu vaccine expired June 30, 2015. These doses should be reported to the Philadelphia Immunization Program by July 31, 2015.

Reporting Flu Vaccine

If you order VFC/VFAAR vaccines online, you should now report the expiring flu vaccines online in KIDS Plus IIS. Register for vaccine returns training on this web form: http://goo.gl/forms/fkQIpsfr5r

If you order vaccines via paper logs, you should report these vaccines using the “Wasted” form for opened vials, and “Expired/Spoiled” form for unopened vials. Fax these forms to 215-238-6939. Discard the wasted vaccine, and set aside the expired/spoiled vaccine.

Read the full message here.

VFC Program: 9-valent HPV Vaccine

Philadelphia VFC Program

Beginning July 1, 2015, the Philadelphia Vaccines For Children (VFC) Program will cutover entirely to supplying the recently licensed recommended 9-valent human papillomavirus (9vHPV) GARDASIL®9 vaccine to replace the currently supplied 4-valent human papillomavirus (4vHPV) GARDASIL®4 vaccine. Both vaccines are manufactured by Merck, Sharpe and Dohme Corp.

Read the full message here.

Recommended 9vHPV Vaccine Immunization

The ACIP recommended 9vHPV for routine vaccination at 11-12 year for males and females. Catch-up vaccination is recommended for females 13-26 years and males up to 21 years and up to 26 years for MSM and immunocompromised males. The ACIP recommendation overrides the FDA approval.

Starting July 1, the Philadelphia VFC Program will no longer offer 4vHPV. That product will be replaced with 9vHPV. The 9vHPV vaccine follows the same recommended immunization schedule as 4vHPV.

For more information please read the March 27, 2015 ACIP recommendations published in the CDC’s MMWR.

Annual Program Re-enrollment

Vaccines for Children (VFC)

All VFC providers must complete the annual VFC Re-enrollment Forms. Please read and complete the re-enrollment forms by Friday, July 10, 2015.

Vaccines for Adults at Risk (VFAAR)

All VFAAR providers must complete the annual VFAAR Re-enrollment Forms. Please read and complete the re-enrollment forms by Friday, July 10, 2015.

KIDS Plus IIS

Please complete the KIDS Plus IIS Confidentiality Agreement and return it by Friday, July 10, 2015.

2015 New Year Immunization Update

This Immunization Update includes information on:

  • Required back-up thermometers
  • Data loggers
  • Provider survey
  • New wastage module in KIDS Plus IIS
  • Annual VFC and VFAAR enrollment
  • KIDS Plus IIS upgrade
  • New ACIP recommended immunization schedules
  • New Immunization Program staff
  • Education materials
  • Wastage policy reminder

Read the full Immunization Update here.

VFAAR Flu Vaccine & Coordinator Update

VFAAR Flu Vaccine Unavailable

There is no more VFAAR flu vaccine for the 2014-15 season. You are still responsible for reporting all administered VFAAR doses to KIDS Plus IIS, and reporting all expired, spoiled and wasted vaccine to VFAAR.

New VFAAR Coordinator

Shumethia Seal starts as the new VFAAR Coordinator today, Monday, December 22. You can contact Shumethia at Shumethia.Seal@phila.gov or 215-685-6424.

Read the full advisory here.

 

Mailing Address

PDPH Immunization Program

500 South Broad Street

2nd Floor

Philadelphia, PA 19146

 

KIDS Plus IIS Hotline

Email: KIDSRegistry@phila.gov

Phone: 215-685-6784

 

Hours of Operation

8:30 am to 5:00 pm

Monday to Friday

(except city holidays)